CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 51 enrolled
Drug / intervention
dasatinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00474812
NCT00474812Phase 2Completed
CompareCT.gov

Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas

National Cancer Institute (NCI)·interventional·Posted May 17, 2007·Updated May 5, 2015

In Brief

A Phase 2 clinical trial evaluating dasatinib, laboratory biomarker analysis, and 1 other intervention for Adenocarcinoma of the Pancreas and 2 related conditions. Completed, enrolled 51 participants across 1 site.

Detailed Summary

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartMay 1, 2007
Primary CompletionJan 1, 2013
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 19.1 years ago

Interventions

dasatinibdrug

laboratory biomarker analysisprocedure

Correlative study

physiologic testingprocedure

Correlative study